Genomic profiling of penile squamous cell carcinoma reveals major biomarkers for efficacy of immunotherapy

Pembrolizumab shows notable antitumour activity for patients with high-risk non–muscle-invasive bladder cancer

Latest in PARP inhibitors and combination therapies for prostate cancer

Plasma miR371 detects MRD and early relapse of germ cell tumours

Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in advanced RCC

Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC

Nivolumab and salvage nivolumab plus ipilimumab for aRCC

Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of muscle-invasive bladder cancer patients

Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial carcinoma after radical resection

Anti-PSMA antibody radiolabeled with 177Lu improves MFS in high-risk nmCRPC

Erdafitinib demonstrates efficacy in intermediate-risk non–muscle-invasive bladder cancer with FGFR alterations

Cell-free utDNA may predict transurethral resection of bladder tumour pathology in non–muscle invasive bladder cancer